ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences, November 05, 2020

ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences LEIDEN, Netherlands, Nov. 5, 2020 /PRNewswire/ — ProteoNic, a leading provider of technology and services for efficient production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Gilead Sciences, Inc. (Nasdaq: GILD).  Under the agreement, Gilead…

ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics, October 20, 2020

LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ — ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement,…

Cytovia Therapeutics Licenses ProteoNic Technology, August 19, 2020

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic Cytovia developing novel CAR NK cell therapy and NK engager antibodies for cancer   August 12, 2020 09:04 ET | Source: Cytovia Therapeutics NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing…